26 May 2022
Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.
16 May 2022
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
10 May 2022
The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.
8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
24 September 2021
Congratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.
20 August 2021
There’s no evidence yet that top-up shots are needed, so let’s help those around the world who urgently need the vaccine - writes Andrew Pollard in an opinion piece for The Guardian.
University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships
9 August 2021
Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.
30 July 2021
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.
30 July 2021
If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
27 July 2021
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
9 July 2021
Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
9 July 2021
'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
28 June 2021
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
28 June 2021
Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
21 June 2021
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
17 June 2021
Read about the topic in Samantha Vanderslott's latest publication.
11 June 2021
Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.